Immuno-biology of Chikungunya and implications for disease intervention

被引：70

作者：

Kam, Yiu-Wing ^{[1
]}

Ong, Edward K. S. ^{[1
]}

Renia, Laurent ^{[1
]}

Tong, Joo-Chuan ^{[2
,3
]}

Ng, Lisa F. P. ^{[1
,3
]}

机构：

[1] ASTAR, Singapore Immunol Network, Singapore 138648, Singapore

[2] ASTAR, Data Min Dept, Inst Infocomm Res, Singapore 138632, Singapore

[3] Natl Univ Singapore, Dept Biochem, Yong Loo Lin Sch Med, Singapore 117597, Singapore

来源：

MICROBES AND INFECTION | 2009年 / 11卷 / 14-15期

关键词：

Chikungunya; Infection; Immune-pathology; Intervention; ROSS RIVER VIRUS; ANTIBODY-DEPENDENT ENHANCEMENT; SEMLIKI-FOREST-VIRUS; CENTRAL-NERVOUS-SYSTEM; INDIAN-OCEAN ISLANDS; MOUSE BRAIN-CELLS; SINDBIS VIRUS; MONOCLONAL-ANTIBODIES; GENE-EXPRESSION; COMPARATIVE IMMUNOGENICITIES;

D O I：

10.1016/j.micinf.2009.09.003

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The re-emergence of Chikungunya fever, an old tropical infectious disease with new characteristics represents a major public health problem with severe social and economic burdens globally. Though Chikungunya has previously been known as a relatively benign disease, its recent re-emergence has caused considerable morbidity with even some cases of fatality. The aggressive waves of the disease are suspected to be due to changes in the virus as well as the vector which makes it appear like a new form of the disease. The study of the human immune response will be crucial in understanding some features of the disease. This review discusses what is currently known on the immuno-biology of Chikungunya and areas that will be important for the development of immune-based antiviral control strategies. (C) 2009 Elsevier Masson SAS. All rights reserved.

引用

页码：1186 / 1196

页数：11

共 109 条

[11] MONOCLONAL-ANTIBODIES TO SINDBIS VIRUS GLYCOPROTEIN-E1 CAN NEUTRALIZE, ENHANCE INFECTIVITY, AND INDEPENDENTLY INHIBIT HEMAGGLUTINATION OR HEMOLYSIS [J].

CHANAS, AC ;

GOULD, EA ;

CLEGG, JCS ;

VARMA, MGR .

JOURNAL OF GENERAL VIROLOGY, 1982, 58 (JAN) :37-46

[12]

CHATTERJ.SN, 1965, INDIAN J EXP BIOL, V3, P227

[13] A mouse model for chikungunya:: Young age and inefficient type-I interferon signaling are risk factors for severe disease [J].

Couderc, Therese ;

Chretien, Fabrice ;

Schilte, Clementine ;

Disson, Olivier ;

Brigitte, Madly ;

Guivel-Benhassine, Florence ;

Touret, Yasmina ;

Barau, Georges ;

Cayet, Nadege ;

Schuffenecker, Isabelle ;

Despres, Philippe ;

Arenzana-Seisdedos, Fernando ;

Michault, Alain ;

Albert, Matthew L. ;

Lecuit, Marc .

PLOS PATHOGENS, 2008, 4 (02)

[14]

Dantzer Robert, 1998, European Cytokine Network, V9, P27

[15] Characterization of epitopes for virus-neutralizing monoclonal antibodies to Ross River virus E2 using phage-displayed random peptide libraries [J].

Davies, JM ;

Cai, YP ;

Weir, RC ;

Rowley, MJ .

VIROLOGY, 2000, 275 (01) :67-76

[16]

De Rose R, 2006, HUM VACCINES, V2, P134

[17] PERSISTENT NONCYTOLYTIC TOGAVIRUS INFECTION OF PRIMARY MOUSE MUSCLE-CELLS [J].

EATON, BT ;

HAPEL, AJ .

VIROLOGY, 1976, 72 (01) :266-271

[18]

Eckels Kenneth H, 2003, Adv Virus Res, V61, P395, DOI 10.1016/S0065-3527(03)61010-9

[19] CHIKUNGUNYA VIRUS VACCINE PREPARED BY TWEEN-ETHER EXTRACTION [J].

ECKELS, KH ;

HARRISON, VR ;

HETRICK, FM .

APPLIED MICROBIOLOGY, 1970, 19 (02) :321-&

[20] Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218 [J].

Edelman, R ;

Tacket, CO ;

Wasserman, SS ;

Bodison, SA ;

Perry, JG ;

Mangiafico, JA .

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2000, 62 (06) :681-685

← 1 2 3 4 5 6 7 8 9 10 →